Polyphosphate delays fibrin polymerisation and alters the mechanical properties of the fibrin network

Thrombosis and Haemostasis

Volumn 116, Issue 5, 2016, Pages 897-903

  Whyte, Claire S ^a   Chernysh, Irina N ^b   Domingues, Marco M ^c   Connell, Simon ^c   Weisel, John W ^b   Ariens, Robert A S ^c   Mutch, Nicola J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Fibrin(ogen); Polymerization; Polyphosphate

Indexed keywords

CALCIUM CHLORIDE; ETHYLENEDIAMINE; FIBRIN; FIBRINOGEN; POLYPHOSPHATE; THROMBIN;

ARTICLE; ATOMIC FORCE MICROSCOPY; BIOMECHANICS; BLOOD CLOTTING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FIBRIN CLOT; FLOW MEASUREMENT; HUMAN; PLASTICITY; POLYMERIZATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; CHEMISTRY;

FIBRIN; FIBRINOGEN; POLYMERIZATION; POLYPHOSPHATES; THROMBIN;

EID: 84994553105     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-01-0062     Document Type: Article

References (39)

1. Fatah K, Hamsten A, Blomback B, et al. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
2. Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
3. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
4. Undas A, Nowakowski T, Ciesla-Dul M, et al. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis 2011; 215: 481-486.
5. Undas A, Zawilska K, Ciesla-Dul M, et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
6. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537.
7. Wolberg AS, Monroe DM, Roberts HR, et al. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 2003; 101: 3008-3013.
8. Scrutton MC, Ross-Murphy SB, Bennett GM, et al. Changes in clot deformability--a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis 1994; 5: 719-723.
9. Undas A, Szuldrzynski K, Stepien E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196: 551-557.
10. Bhasin N, Ariens RA, West RM, et al. Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. J Vasc Surg 2008; 48: 1497-1503, 503 e1.
11. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361.
12. Ruiz FA, Lea CR, Oldfield E, et al. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279: 44250-44257.
13. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
14. Smith SA, Mutch NJ, Baskar D, et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
15. Nickel KF, Ronquist G, Langer F, et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015; 126: 1379-1389.
16. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119: 5972-5979.
17. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008; 112: 2810-2816.
18. Mutch NJ, Engel R, Uitte de Willige S, et al. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115: 3980-3988.
19. Zhu S, Travers RJ, Morrissey JH, et al. FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow. Blood 2015; 126: 1494-1502.
20. Smith SA, Choi SH, Collins JN, et al. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012; 120: 5103-5110.
21. Travers RJ, Shenoi RA, Kalathottukaren MT, et al. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014; 124: 3183-3190.
22. Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116: 4353-4359.
23. Chernysh IN, Nagaswami C, Weisel JW. Visualisation and identification of the structures formed during early stages of fibrin polymerisation. Blood 2011; 117: 4609-4614.
24. Allan P, Uitte de Willige S, Abou-Saleh RH, et al. Evidence that fibrinogen gamma’ directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J Thromb Haemost 2012; 10: 1072-1080.
25. Evans RM, Tassieri M, Auhl D, et al. Direct conversion of rheological compliance measurements into storage and loss moduli. Phys Rev E Stat Nonlin Soft Matter Phys 2009; 80: 012501.
26. Choi SH, Collins JN, Smith SA, et al. Phosphoramidate end labeling of inorganic polyphosphates: facile manipulation of polyphosphate for investigating and modulating its biological activities. Biochemistry 2010; 49: 9935-9941.
27. Gray MJ, Wholey WY, Wagner NO, et al. Polyphosphate is a primordial chaperone. Mol Cell 2014; 53: 689-699.
28. Donovan AJ, Kalkowski J, Smith SA, et al. Size-controlled synthesis of granular polyphosphate nanoparticles at physiologic salt concentrations for blood clotting. Biomacromolecules 2014; 15: 3976-3984.
29. Blomback B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538.
30. Chernysh IN, Weisel JW. Dynamic imaging of fibrin network formation correlated with other measures of polymerisation. Blood 2008; 111: 4854-4861.
31. Carr ME, Jr., Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 1978; 11: 46-50.
32. Janmey PA, Ferry JD. Gel formation by fibrin oligomers without addition of monomers. Biopolymers 1986; 25: 1337-1344.
33. Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 5 (Suppl 1): 116-124.
34. Weisel JW, Medved L. The structure and function of the alpha C domains of fibrinogen. Ann NY Acad Sci 2001; 936: 312-327.
35. Gorkun OV, Veklich YI, Medved LV, et al. Role of the alpha C domains of fibrin in clot formation. Biochemistry 1994; 33: 6986-6997.
36. Medved LV, Gorkun OV, Manyakov VF, et al. The role of fibrinogen alpha C-domains in the fibrin assembly process. FEBS Lett 1985; 181: 109-112.
37. Collet JP, Moen JL, Veklich YI, et al. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood 2005; 106: 3824-3830.
38. Veklich YI, Gorkun OV, Medved LV, et al. Carboxyl-terminal portions of the alpha chains of fibrinogen and fibrin. Localisation by electron microscopy and the effects of isolated alpha C fragments on polymerisation. J Biol Chem 1993; 268: 13577-13585.
39. Lawrence MJ, Sabra A, Mills G, et al. A new biomarker quantifies differences in clot microstructure in patients with venous thromboembolism. Br J Haematol 2015; 168: 571-575.